MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2767-9764.crc-21-0161

Медицинская библиотека · Cancer research communications · 2022

TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.

Carideo Cunniff Elizabeth, Sato Yosuke, Mai Doanh, Appleman Vicky A, Iwasaki Shinji, Kolev Vihren, Matsuda Atsushi, Shi Judy, Mochizuki Michiyo, Yoshikawa Masato, Huang Jian, Shen Luhua, Haridas Satyajeet, Shinde Vaishali, Gemski Chris, Roberts Emily R, Ghasemi Omid, Bazzazi Hojjat, Menon Saurabh, Traore Tary, Shi Pu, Thelen Tennille D, Conlon Joseph, Abu-Yousif Adnan O, Arendt Christopher, Shaw Michael H, Okaniwa Masanori

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

UNLABELLED: Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing.

SIGNIFICANCE: TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.

Для цитирования: Carideo Cunniff Elizabeth, Sato Yosuke, Mai Doanh, Appleman Vicky A, Iwasaki Shinji, Kolev Vihren, Matsuda Atsushi, Shi Judy, Mochizuki Michiyo, Yoshikawa Masato, Huang Jian, Shen Luhua, Haridas Satyajeet, Shinde Vaishali, Gemski Chris, Roberts Emily R, Ghasemi Omid, Bazzazi Hojjat, Menon Saurabh, Traore Tary, Shi Pu, Thelen Tennille D, Conlon Joseph, Abu-Yousif Adnan O, Arendt Christopher, Shaw Michael H, Okaniwa Masanori. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.. Cancer research communications. 2022. DOI: 10.1158/2767-9764.crc-21-0161.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.